Corebridge Financial Inc. Lowers Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Corebridge Financial Inc. decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,805 shares of the medical instruments supplier’s stock after selling 844 shares during the quarter. Corebridge Financial Inc.’s holdings in LeMaitre Vascular were worth $996,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Smartleaf Asset Management LLC increased its stake in LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC grew its holdings in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 117 shares in the last quarter. KBC Group NV increased its position in LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares during the last quarter. Empowered Funds LLC bought a new stake in LeMaitre Vascular in the fourth quarter worth $150,000. Finally, SG Americas Securities LLC purchased a new position in shares of LeMaitre Vascular in the 4th quarter worth $158,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LMAT. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Lake Street Capital increased their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $79.78 on Friday. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of 43.60, a PEG ratio of 2.22 and a beta of 0.89. The company has a 50-day moving average of $91.62 and a 200 day moving average of $94.15. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. The firm had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a $0.20 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular’s payout ratio is presently 41.24%.

Insider Buying and Selling

In other news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.79% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.